|drug1205||Exercise brochure Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.
Description: Prevalence and risk-factors for SARS-CoV-2 infectionMeasure: Prevalence and risk-factors for SARS-CoV-2 infection Time: inclusion during 4 months
Description: Prevalence and risk-factors for COVID-19Measure: Prevalence and risk-factors for COVID-19 Time: inclusion during 4 months
Description: Durability of IgG positivity/immunityMeasure: Durability of IgG positivity Time: 12 months
Data processed on December 13, 2020.